STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing…
seekingalpha.com
GERN(GERN)
GERN
Next earnings: Aug 5, 2026 · Before open
Signal
Bearish Setup2↓
PRICE
Prev Close
1.40
Open
1.40
Day Range1.29 – 1.40
1.29
1.40
52W Range1.04 – 2.01
1.04
2.01
26% of range
VOLUME & SIZE
Avg Volume
19.2M
FUNDAMENTALS
P/E Ratio
-11.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.39
Market-like
Performance
1D
-7.86%5D
-14.00%1M↓
-23.67%3M
-21.82%6M↑
+15.18%YTD
-2.27%1Y
+6.61%Best: 6M (+15.18%)Worst: 1M (-23.67%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +69% YoY · 87% gross marginValuation
FAIR
P/E not availableHealth
WEAK
CR 6.8 · FCF negativeLean Bullish
Key MetricsTTM
Market Cap$827.56M
Revenue TTM$196.12M
Net Income TTM-$69.59M
Free Cash Flow-$126.30M
Gross Margin86.6%
Net Margin-35.5%
Operating Margin-19.1%
Return on Equity-28.9%
Return on Assets-13.0%
Debt / Equity1.10
Current Ratio6.78
EPS TTM$-0.10
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
1 strong2 watch3 concern
35/100Liquidity
6.78Strong
Leverage
1.10Watch
Coverage
-1.2xConcern
ROE
-28.9%Concern
ROIC
-7.8%Concern
Cash
$79MWatch
ANALYST COVERAGE20 analysts
BUY
▲ +365.1%upside to target
L $4.00
Med $6.00consensus
H $8.00Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
●
✗RSI RangeRSI 40 — Bearish momentum
Volume
●
✗Volume FlowDistribution — institutional selling
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 6.78 — healthy liquidity
Upcoming Events
EEarnings Report · Before OpenMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 17, 2026
In 93 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
▼ DowntrendGolden Cross · 50D leads 200D by 12.4%
-17.8% vs SMA 50 · -7.5% vs SMA 200
Momentum
RSI40.1Momentum fading
MACD-0.06Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$2.01+55.8%
EMA 50
$1.54+19.0%
EMA 200
$1.44+11.4%
Current
$1.29
52W Low
$1.04-19.4%
52-Week RangeMid-range
$1.0426th %ile$2.01
Squeeze SetupVolume-based
Distribution PressureHeavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
20-Day Money Flow
Acc days:2
Dist days:3
Edge:+1 dist
Volume Context
Avg Vol (50D)18.5M
Recent Vol (5D)
23.8M+29%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 5 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $186.3M $185.4M–$187.3M | — | -$0.10 | — | ±14% | High5 |
FY2026(current) | $233.8M $231.6M–$237.7M | ▲ +25.5% | -$0.02 | — | ±50% | High5 |
FY2027 | $333.1M $304.6M–$389.9M | ▲ +42.5% | $0.07 | — | ±50% | High5 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryGERN
Last 8Q
+26.0%avg beat
Beat 6 of 8 quarters↑ Estimates rising+9%
Q3'24
+56%
Q4'24
—
Q1'25
+25%
Q2'25
+33%
Q3'25
+18%
Q4'25
—
Q1'26
+67%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →4 Buys/2 SellsNet Buying
Robertson MichelleCFO
$19K
Feb 18
SELL
Lawlis V BryanDir
$16K
May 9
BUY
Samuels Scott AlanEVP, Chief Leg…
$24K
Feb 27
BUY
Scarlett John ADir
$22K
Feb 27
BUY
Ziegler JamesEVP, Chief Co…
$160K
Feb 27
BUY
Grethlein Andrew JCOO
$3.1M
Jul 8
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
BlackRock, Inc.
47.3M▲2
Soleus Capital Management, L.P.
41.5M▲3
Clearbridge Investments, LLC
19.6M▲4
DEUTSCHE BANK AG\
5.2M▲5
Pale Fire Capital SE
4.9M▲6
NORTHERN TRUST CORP
4.9M▲7
Candriam S.C.A.
3.9M▲8
VANGUARD FIDUCIARY TRUST CO
3.8M▲News & Activity
GERN News
20 articles · 4h ago
Snail returns to profitability in Q1 as revenue surges - ICYMI
proactiveinvestors.com
kneat.com Q1 Earnings Call Highlights
marketbeat.com
Neo Performance Materials Q1 Earnings Call Highlights
marketbeat.com
Northland Power Q1 Earnings Call Highlights
marketbeat.com
Terreno Realty Corporation: This Coastal Industrial REIT Is A Buy
seekingalpha.com
Users turn to jailbreaking their older Kindles as Amazon ends support
techcrunch.com
Why Investors Need to Take Advantage of These 2 Retail and Wholesale Stocks Now
zacks.com
Value, Quality, Momentum, And Lower Volatility In One Emerging Markets Fund
247wallst.com
Louisiana-Pacific: A Good Siding Business Offset By A Weak OSB Market
seekingalpha.com
Tesla raises prices of Model Y cars in the US
reuters.com
A Gemini-Fueled Fitbit Could Be the Muscle That Google's Smart Glasses Need
cnet.com
How MLB's and T-Mobile's ABS Challenge System Corrects Strike Calls in Seconds
cnet.com
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
seekingalpha.com
A Major Catalyst Is Emerging For BDCs That The Market Is Completely Missing
seekingalpha.com
Bill Gates Just Did the Unthinkable — He Sold Every Last Share of Microsoft Stock
247wallst.com
Let's Talk About Your Big “But”
etftrends.com
Global oil stockpiles could hit record lows if Strait of Hormuz remains closed
cnbc.com
SPHQ Outpaced JQUA by 500 Basis Points Over Five Years Despite Being the Riskier Trade
247wallst.com
Berkshire's new CEO overhauls portfolio, dumping a slate of stocks
cnbc.com
About
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
John Scarlett
Website
Joseph Emile EidExecutive Vice President of Research & Development and Chief Medical Officer
Ahmed ElNawawiExecutive Vice President & Chief Commercial Officer
Bryan RidgellSenior Vice President of Portfolio & Project Management and Chief of Staff
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
GERN◀ | $1.29 | -7.86% | $828M | — | +13882.5% | -4665.1% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.67% | — | 50.3 | +343833.0% | -4168.4% | 1500 |